Keros Therapeutics (KROS) Competitors $11.39 -0.02 (-0.18%) Closing price 04:00 PM EasternExtended Trading$11.40 +0.01 (+0.09%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KROS vs. BEAM, CNTA, MESO, IDYA, AGIO, APGE, TARS, IOVA, AMPH, and IRONShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Mesoblast (MESO), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Amphastar Pharmaceuticals (AMPH), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Beam Therapeutics Centessa Pharmaceuticals Mesoblast IDEAYA Biosciences Agios Pharmaceuticals Apogee Therapeutics Tarsus Pharmaceuticals Iovance Biotherapeutics Amphastar Pharmaceuticals Disc Medicine Keros Therapeutics (NASDAQ:KROS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, community ranking, risk and valuation. Do institutionals and insiders hold more shares of KROS or BEAM? 71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by company insiders. Comparatively, 4.2% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, KROS or BEAM? Keros Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Which has better valuation & earnings, KROS or BEAM? Beam Therapeutics has higher revenue and earnings than Keros Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKeros Therapeutics$150K2,969.38-$152.99M-$5.21-2.11Beam Therapeutics$377.71M5.51-$132.53M-$1.76-14.28 Does the MarketBeat Community believe in KROS or BEAM? Keros Therapeutics received 6 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 69.32% of users gave Keros Therapeutics an outperform vote while only 55.56% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformKeros TherapeuticsOutperform Votes6169.32% Underperform Votes2730.68% Beam TherapeuticsOutperform Votes5555.56% Underperform Votes4444.44% Do analysts recommend KROS or BEAM? Keros Therapeutics currently has a consensus price target of $52.56, indicating a potential upside of 378.00%. Beam Therapeutics has a consensus price target of $47.67, indicating a potential upside of 89.60%. Given Keros Therapeutics' higher possible upside, equities analysts clearly believe Keros Therapeutics is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 0 Sell rating(s) 6 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.57Beam Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.92 Is KROS or BEAM more profitable? Beam Therapeutics has a net margin of -41.07% compared to Keros Therapeutics' net margin of -27,890.94%. Beam Therapeutics' return on equity of -16.22% beat Keros Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Keros Therapeutics-27,890.94% -41.74% -38.42% Beam Therapeutics -41.07%-16.22%-10.94% Does the media favor KROS or BEAM? In the previous week, Keros Therapeutics had 26 more articles in the media than Beam Therapeutics. MarketBeat recorded 33 mentions for Keros Therapeutics and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.03 beat Keros Therapeutics' score of -0.09 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Keros Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 10 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral SummaryBeam Therapeutics beats Keros Therapeutics on 11 of the 19 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$445.57M$6.57B$5.42B$9.27BDividend YieldN/A2.96%5.37%3.99%P/E Ratio-2.119.8588.8317.53Price / Sales2,969.38333.361,227.6678.88Price / CashN/A64.1243.6036.96Price / Book0.995.104.994.72Net Income-$152.99M$154.90M$117.89M$224.57M7 Day Performance5.52%1.39%1.86%1.56%1 Month Performance-35.44%1.55%3.81%5.15%1 Year Performance-79.93%4.84%26.44%21.24% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics2.7949 of 5 stars$11.39-0.2%$52.56+361.4%-78.5%$461.41M$150,000.00-2.19100Analyst DowngradeAnalyst RevisionNews CoverageGap DownBEAMBeam Therapeutics3.485 of 5 stars$24.66-6.6%$47.67+93.3%+3.5%$2.04B$349.64M-14.01510CNTACentessa Pharmaceuticals3.0174 of 5 stars$15.06-3.7%$25.83+71.5%+103.2%$1.99B$6.85M-9.84200Insider TradeNews CoverageMESOMesoblast0.9533 of 5 stars$17.18-4.0%$13.50-21.4%+839.6%$1.97B$5.90M0.0080Gap DownIDYAIDEAYA Biosciences4.0682 of 5 stars$22.72-5.5%$53.67+136.2%-43.6%$1.96B$3.92M-9.7580Analyst RevisionAGIOAgios Pharmaceuticals3.7174 of 5 stars$34.37-0.1%$56.33+63.9%+52.9%$1.96B$32.87M3.03390Short Interest ↑APGEApogee Therapeutics2.332 of 5 stars$40.30-1.8%$89.71+122.6%+17.1%$1.81BN/A-16.6591TARSTarsus Pharmaceuticals1.5907 of 5 stars$47.41-10.0%$54.20+14.3%+99.1%$1.81B$129.62M-12.4450Analyst ForecastIOVAIovance Biotherapeutics4.1456 of 5 stars$5.92-7.5%$23.00+288.5%-24.4%$1.80B$90.86M-3.97500AMPHAmphastar Pharmaceuticals4.5097 of 5 stars$37.51+3.2%$60.33+60.8%-34.5%$1.80B$723.55M12.501,620IRONDisc Medicine3.0159 of 5 stars$58.32-1.6%$87.50+50.0%-6.5%$1.74BN/A-14.6530Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap Down Related Companies and Tools Related Companies Beam Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Mesoblast Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives Apogee Therapeutics Alternatives Tarsus Pharmaceuticals Alternatives Iovance Biotherapeutics Alternatives Amphastar Pharmaceuticals Alternatives Disc Medicine Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KROS) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KROS Stock Alerts